Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | MURANO update: MRD negativity in CLL

The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL), for which further results were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. In this interview, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from Leeds Teaching Hospital NHS Trust, Leeds, UK, shares the significant advantages of venetoclax plus rituximab, highlighting the higher levels of MRD negativity produced. Prof. Hillmen notes how this highlights a future with longer remission periods, even after treatment has ceased.